Finerenone (Kerendia, BAY94-8862) clinical trials
4 indexed studies · 4 currently recruiting
- RecruitingPHASE3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
This study is for children aged 6 months to 17 years with long-term kidney disease (CKD) and too much protein in their urine. It tests a new medicine called finerenone to see if it can improve kidney health alongside existing treatments. Researchers want to check how safe and effective it is.
For: Chronic Kidney Disease · ProteinuriaUnited States · Argentina · Australia - Not yet recruitingPHASE3
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
This study is testing a new medicine called finerenone for children and young adults with a type of heart failure where the heart struggles to pump blood. Researchers want to see how safe it is and how well it works over time.
For: Left Ventricular Systolic Dysfunction · Heart Failure (Pediatric)United States · Argentina · Austria - RecruitingPHASE3
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
This study is looking into a new medicine, finerenone, for children aged 6 months to 17 years with heart failure. It aims to see if finerenone, when added to their usual treatment, can help their heart pump better and if it is safe to use.
For: Left Ventricular Systolic Dysfunction · Heart Failure (Pediatric)United States · Argentina · Austria - RecruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
For: Chronic Kidney Disease · Proteinuria · ChildrenUnited States · Argentina · Australia